Patents Assigned to Mai De Ltd.
  • Patent number: 7820716
    Abstract: The present invention is directed to two new polymorph Form V and Form F of desvenlafaxine succinate, to processes of their preparations, pharmaceutical composition comprising such materials and their use in therapy. Form V is prepared from recrystallizing desvenlafaxine succinate in a mixture of tetrahydrofuran and ethanol. Form F is obtained from recrystallization of desvenlafaxine succinate in a mixture of cyclohexane and polar solvents such as ethanol, THF, methanol or isopropyl alcohol.
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: October 26, 2010
    Assignee: Mai De Ltd
    Inventors: Cai Gu Huang, Hui Min He Huang
  • Patent number: 7625911
    Abstract: The present invention relates to novel amorphous form of [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl) (erlotinib hydrochloride), to solid amorphous dispersion of erlotinib hydrochloride and a carrier such as PVP or solid PEG, to processes for their preparations, to pharmaceutical compositions containing them and to method of treatment using the same. The amorphous form or solid amorphous dispersion of erlotinib hydrochloride obtained in this invention is useful in preparing pharmaceutical dosage forms.
    Type: Grant
    Filed: January 12, 2005
    Date of Patent: December 1, 2009
    Assignee: Mai De Ltd.
    Inventor: Le Huang
  • Patent number: 7351710
    Abstract: The present invention is directed to amorphous form of indiplon, to processes for preparing said amorphous form, to pharmaceutical compositions containing the same, and to method of treatment using the same. Additionally, the present invention also relates to the preparation of solid amorphous dispersion of indiplon and a carrier which includes PVP and solid PEG etc.
    Type: Grant
    Filed: February 6, 2006
    Date of Patent: April 1, 2008
    Assignee: Mai De Ltd.
    Inventors: Le Huang, Hui Min He Huang
  • Patent number: 7241800
    Abstract: The present invention relates to novel anhydrous amorphous forms of bis[(E)[4-(4-fluorophenyl)isopropyl[methyl(methylsulfonyl)amino]pyrimidinyl](3R,5S)-3,5-dihydroxyhept enoic acid]calcium salt (rosuvastatin calcium), (±)7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)3,5-dihydroxy heptenoic acid monosodium salt (fluvastatin sodium) and bis[(E)-3,5-dihydroxy-7-[4?-(4?-fluorophenyl)-2?-cyclopropyl-quinolin-3?-hept-6-enoic acid]calcium salt (pitavastatin calcium), to processes for their preparation, to pharmaceutical compositions containing them and to methods of treatment using the same. The rosuvastatin calcium, pitavastatin calcium and fluvastatin sodium obtained are known valuable agents useful in treating hyperlipidemia and hypercholestrolemia.
    Type: Grant
    Filed: March 17, 2004
    Date of Patent: July 10, 2007
    Assignee: Mai De Ltd.
    Inventor: Le Huang